AstraZeneca and Oracle have announced a global collaboration to explore how artificial intelligence (AI), real-world health data and cloud-based technologies can improve clinical trial efficiency, identify eligible patients earlier and connect medical research more effectively with routine healthcare. The agreement aims to address persistent challenges in clinical research, particularly patient recruitment, safety monitoring and the translation of scientific evidence into clinical practice.

Under the non-binding agreement, AstraZeneca will contribute its expertise in drug development, clinical research and regulatory affairs, while Oracle will provide its healthcare data capabilities, cloud infrastructure, AI tools and clinical workflow technologies. The companies have not disclosed the financial terms of the collaboration.

The partnership will initially explore applications across oncology; cardiovascular, renal and metabolic diseases; respiratory conditions; immunology; and rare diseases. The proposed applications include identifying suitable candidates for clinical trials, supporting earlier disease detection, improving drug-safety monitoring and generating real-world evidence throughout a medicine’s lifecycle.

The first programme will focus on hypertension care and clinical research in Abu Dhabi, in partnership with UAE-based healthcare company M42. The initiative aims to help clinical teams identify patients whose blood pressure remains uncontrolled, support treatment aligned with clinical guidelines and improve recruitment for hypertension-related clinical trials.

Patient recruitment remains a major operational challenge for clinical research, as potential participants must meet specific eligibility criteria and may not know that relevant trials are available. AI-assisted analysis of appropriately governed health data could help care teams identify suitable candidates earlier, subject to clinical assessment and consent requirements.

The companies also plan to explore a continuous-learning model that connects insights from clinical research with evidence generated during routine care. This approach could inform future study design, strengthen safety monitoring and support more evidence-based treatment decisions.

Data privacy and governance will be central to the initiative. The collaboration is expected to use de-identified real-world data under appropriate privacy and security safeguards. Each project will remain subject to applicable legal, ethical, regulatory and institutional approvals.

The partnership reflects a growing focus on applying AI beyond drug discovery to the operational and clinical stages of pharmaceutical development. Its impact will depend on whether the proposed applications can demonstrate measurable improvements in patient identification, trial efficiency and the integration of research evidence into everyday care.